Antithrombotic-Associated Bleeding
In this episode, Sam Ashoo, MD, Dr. Christopher Baugh, MD, MBA, and Dr. Xin Qi, MD, discuss the October 2026 Emergency Medicine Practice article, Antithrombotic-Associated Bleeding: Management in the Emergency Department. 1:18 — Guest introductions 1:58 — Why the authors chose this topic 3:11 — Epidemiology 4:27 — Why DOACs over warfarin 5:15 — Bleeding trends 6:55 — Overlapping antithrombotic regimens 8:09 — Reversibility of agents 9:38 — Bedside priorities 11:31 — Bleeding patterns by drug class & three groups 13:50 — Antithrombotics & traumatic bleeding risk 14:26 — Pre-hospital considerations 16:09 — Indications for antithrombotic use & risk of reversing 17:54 — Gray-area decisions 19:02 — Initial resuscitation 20:08 — Blood product ratios 21:24 — PATCH trial 22:04 — TXA evidence 23:36 — GI bleed adjuncts 24:31 — Critical site bleeds 27:20 — Endoscopy timing 30:00 — Reversal agents 32:50 — Idarucizumab for dabigatran 33:54 — Antiplatelet reversal 36:15 — Warfarin reversal 38:36 — Protamine for heparin/LMWH 39:37 — Fibrinolytic reversal 40:14 — Pre-procedural antithrombotic management 42:39 — Emerging labs 43:50 — Wrap-up & closing promo Subscribers, take the CME test here. Emergency Medicine Residents, get your free subscription by writing [email protected]